Skip to main content

United Health Products, Inc.

corporate_fare Company Profile

United Health Products, Inc.

UEEC·OTC·Industrial Applications And Services·CIK 0001096938

United Health Products, Inc. (UHP) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. The company's gauze product, CelluSTAT®, is made from cotton and designed to absorb fluid from superficial wounds and help control bleeding. UHP is currently seeking regulatory approval to sell its hemostatic gauze product line in the U.S. Class III and European CE Mark human surgical markets. As part of its business strategy, UHP is pursuing FDA Premarket Approval (PMA) for its CelluSTAT Hemostatic Gauze products. In March 2024, the company submitted a full PMA application to the FDA. The FDA responded in June 2024 with a "Deficiencies Letter" containing approximately 40 specific comments and requests for additional information regarding the device description, sterility and shelf life, clinical and performance testing, and biocompatibility sections of the application. From September 23 through October 4, 2024, the FDA conducted a Bioresearch Monitoring Program (BIMO) Inspection of UHP's records and procedures related to its 2019 clinical study, subsequently issuing Inspectional Observations on Form 483. In October 2024, UHP and the FDA held a virtual meeting to discuss the Deficiencies Letter. During this discussion, UHP highlighted the results of its 2019 clinical trial, which involved 232 patients (118 treated with its hemostatic gauze). This study demonstrated statistically superior performance in time to hemostasis for CelluSTAT compared to Ethicon's Surgicel Original, the standard of care. The study also indicated no heterogeneity of results across procedure categories, surgeons, or clinical sites, suggesting the results are both poolable and generalizable. Furthermore, none of the adverse events during the study were attributed to UHP's hemostatic gauze product.

United Health Products, Inc. (OTC:UEEC) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 8 items for UEEC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 8/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for UEEC spans 10-Q, 8-K, 424B3, 10-K.

Recent high-impact activity:

  • United Health Products Q3: $5,588 Cash, Going Concern, and Not Enough Authorized Shares
  • United Health Products Q2 2026: Cash Drops to $24K, Going Concern Warning Reiterated
  • United Health Products Enlists NAMSA to Lead Pivotal Clinical Study for FDA Approval
  • United Health Products Confirms Share Sales Amidst Dire Financial State
  • United Health Products Reports Near-Zero Cash, Ineffective Controls, and Ongoing Going Concern Warning

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$2.67M
Diluted EPS
-$0.01
Op. Cash Flow
-$1.19M
Operating Income
-$2.26M
Cash & Equivalents
$65.25K
Debt / Equity
0.00×
Shares Outstanding
258.69M sh
Source: 10-K · filed 2026-04-15 · accession 0001477932-26-002286

Short Interest & Short Volume

On November 20, 2026, 35.0% of UEEC volume reported to FINRA trade-reporting facilities was marked short.

Daily short volume (FINRA facilities)35.0% of 42,800 shares on November 20, 2026
5-day average short volume26.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with U →
$0.0349 -3.86% today
52-week range · as of 2026-11-17 $0.0285 – $0.12
Market cap
$9.29M
Volume
42.8K (0.2× avg)
3-mo avg 179.7K
Live data · 2026-11-22 04:50 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed UEEC - Latest Insights

UEEC
Nov 17, 2026, 3:46 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.046
Real-time Price: $0.0349 info
Change: -$0.0111 (-24%) info
Market Cap: $9.288M info
UEEC
Aug 14, 2026, 2:45 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.044025
Real-time Price: $0.0349 info
Change: -$0.009125 (-21%) info
Market Cap: $9.288M info
UEEC
Jul 10, 2026, 12:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0513
Real-time Price: $0.0349 info
Change: -$0.0164 (-32%) info
Market Cap: $9.288M info
UEEC
May 22, 2026, 4:05 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.05455
Real-time Price: $0.0349 info
Change: -$0.01965 (-36%) info
Market Cap: $9.288M info
UEEC
May 15, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.0652
Real-time Price: $0.0349 info
Change: -$0.0303 (-46%) info
Market Cap: $9.288M info
UEEC
May 14, 2026, 4:05 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $0.0678
Real-time Price: $0.0349 info
Change: -$0.0329 (-49%) info
Market Cap: $9.288M info
UEEC
Apr 15, 2026, 5:11 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.0637
Real-time Price: $0.0349 info
Change: -$0.0288 (-45%) info
Market Cap: $9.288M info
UEEC
Jan 15, 2026, 5:01 PM EST
Filing Type: S-1
Importance Score:
8
Price at Filing: $0.0619
Real-time Price: $0.0349 info
Change: -$0.027 (-44%) info
Market Cap: $9.288M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets